About
Effective Drug Delivery to the Brain
To date, many brain conditions are poorly medicated due to limitations in drug-delivery prevent treating patients efficiently. The prominent reason is the Blood Brain Barrier (BBB), which prevents most therapeutic molecules from reaching the brain – and severely limits the arsenal of brain therapeutics.
NucleoTech is developing carriers that deliver a variety of drug-classes across the BBB, including biologics and RNA drugs. The company utilizes the BBBs own transfer mechanisms to allow therapeutic molecules through, by using nanobodies (also called Single Domain Antibodies) as carrier molecules that shuttle therapeutics into the brain by the process of Receptor-Mediated Transcytosis.
Identity
| Name | NucleoTech |
|---|---|
| Slug | nucleotech |
| Type / kind | startup |
| Source _id | fT2BhcmwhhGOMdYXYMZ1OkPSE5ZOnpWAstebG59543mUzO3Tk2B8Cl |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Rehovot |
| HQ address | Rehovot, Israel |
Web & social
| Website | https://nucleo-tech.com/cgi-sys/suspendedpage.cgi |
|---|---|
| https://www.linkedin.com/company/80056634 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
nanotechnologybrain-disorderpharmaceuticalsdrug-delivery
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}